Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Cartesian Therapeutics (RNAC) over the last 11 years, with Q3 2025 value amounting to -$1.3 million.

  • Cartesian Therapeutics' Cash from Investing Activities rose 7915.79% to -$1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.3 million, marking a year-over-year decrease of 18112.11%. This contributed to the annual value of -$8.7 million for FY2024, which is 12525.93% down from last year.
  • Latest data reveals that Cartesian Therapeutics reported Cash from Investing Activities of -$1.3 million as of Q3 2025, which was up 7915.79% from -$2.6 million recorded in Q2 2025.
  • Over the past 5 years, Cartesian Therapeutics' Cash from Investing Activities peaked at $28.1 million during Q1 2023, and registered a low of -$29.9 million during Q3 2022.
  • Moreover, its 5-year median value for Cash from Investing Activities was -$838500.0 (2024), whereas its average is -$624277.8.
  • Data for Cartesian Therapeutics' Cash from Investing Activities shows a peak YoY increase of 595662.65% (in 2021) and a maximum YoY decrease of 1652592.59% (in 2021) over the last 5 years.
  • Quarter analysis of 5 years shows Cartesian Therapeutics' Cash from Investing Activities stood at $9.7 million in 2021, then plummeted by 43.54% to $5.5 million in 2022, then increased by 18.36% to $6.5 million in 2023, then plummeted by 105.45% to -$354000.0 in 2024, then tumbled by 264.97% to -$1.3 million in 2025.
  • Its Cash from Investing Activities was -$1.3 million in Q3 2025, compared to -$2.6 million in Q2 2025 and -$1.1 million in Q1 2025.